The value of ~(18)F-FDG PET and ~(18)F-FDG PET/CT in clinical evaluation of sarcoma / 肿瘤

ABSTRACT

As a functional imaging method, positron emission tomography (PET) is widely used in tumor diagnosis, pathological classification, stage assessment, and clinical outcome evaluation. Combination of metabolic information acquired from ~(18)F-fluorodeoxyglucose (~(18)F-FDG) PET with pathological grading results is helpful for further defining the grade of sarcomas and predicting prognosis. ~(18)F-FDG PET appears to be superior to other imaging modalities in detecting bone metastases or pulmonary metastases of sarcoma patients, so it could be used in clinical staging and restaging of sarcoma. Tumor-to-background ratio (TBR) and standardized uptake value (SUV) are two important parameters for quantitative analysis and are helpful for assessing chemotherapy response of tumor. PET imaging offers important information to help maximize the clinical benefit of patients with sarcoma. This article reviews the clinical value of ~(18)F-FDG PET and ~(18)F-FDG PET/CT in diagnosis of sarcoma.